Multiple nano-drug delivery systems for intervertebral disc degeneration: Current status and future perspectives
Source abstract
Abstract
Low back pain (LBP) is a common disease that imposes a huge social and economic burden on people. Intervertebral disc (IVD) degeneration (IVDD) is often considered to be the leading cause of LBP and further aggravate and cause serious spinal problems. The established treatment strategy for IVDD consists of physiotherapy, pain medication by drug therapy, and, if necessary, surgery, but none of them can be treated from the etiology; that is, it cannot fundamentally reverse IVD and reconstruct the mechanical function of the spine. With the development of nanotechnology and regenerative medicine, nano-drug delivery systems (NDDSs) have improved treatment results because of their good biodegradability, biocompatibility, precise targeted specific drug delivery, prolonged drug release time, and enhanced drug efficacy, and various new NDDSs for drugs, proteins, cells, and genes have brought light and hope for the treatment of IVDD. This review summarizes the research progress of NDDSs in the treatment of IVDD and provides prospects for using NDDSs to address the challenges of IVDD. We hope that the ideas generated in this review will provide insight into the precise treatment of IVDD.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Spine and Intervertebral Disc Pathology · Musculoskeletal pain and rehabilitation · Anesthesia and Pain Management
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. 3D assessment of intervertebral disc degeneration in zebrafish identifies changes in bone density that prime disc disease10.1038/s41413-021-00156-y ↗
2. Low back pain: a call for action10.1016/S0140-6736(18)30488-4 ↗
3. Mechanisms of endogenous repair failure during intervertebral disc degeneration10.1016/j.joca.2018.08.021 ↗
4. Degeneration of the intervertebral disc10.1186/ar629 ↗
5. Economic burden of chronic pain10.1586/14737167.6.5.591 ↗
6. The prevalence and years lived with disability caused by low back pain in China, 1990 to 2016: findings from the global burden of disease study 201610.1097/j.pain.0000000000001396 ↗
7. Genetic factors in intervertebral disc degeneration10.1016/j.gendis.2016.04.005 ↗
8. Etiology for degenerative disc disease10.1016/S1001-9294(16)30049-9 ↗
9. Lumbar intervertebral disc degeneration associated with axial and radiating low back pain in ageing SPARC-null mice10.1016/j.pain.2012.01.027 ↗
10. The role of IL-1β and TNF-α in intervertebral disc degeneration10.1016/j.biopha.2020.110660 ↗
11. MAPK/ERK signaling pathway: a potential target for the treatment of intervertebral disc degeneration10.1016/j.biopha.2021.112170 ↗
12. Developments in intervertebral disc disease research: pathophysiology, mechanobiology, and therapeutics10.1007/s12178-014-9253-8 ↗
13. Molecular basis of intervertebral disc degeneration and herniations: what are the important translational questions?10.1007/s11999-014-3774-8 ↗
14. Role of cytokines in intervertebral disc degeneration: pain and disc content10.1038/nrrheum.2013.160 ↗
15. Cell-based strategies for IVD repair: clinical progress and translational obstacles10.1038/s41584-020-00568-w ↗
16. Application of stem cells in the repair of intervertebral disc degeneration10.1186/s13287-022-02745-y ↗
17. Intervertebral disc regeneration: from cell therapy to the development of novel bioinspired endogenous repair strategies10.1016/j.addr.2018.04.017 ↗
18. Drug delivery in intervertebral disc degeneration and osteoarthritis: selecting the optimal platform for the delivery of disease-modifying agents10.1016/j.jconrel.2020.08.041 ↗
19. Delivery systems for the treatment of degenerated intervertebral discs10.1016/j.addr.2014.10.024 ↗
20. Lessons learned from intervertebral disc pathophysiology to guide rational design of sequential delivery systems for therapeutic biological factors10.1016/j.addr.2019.08.007 ↗
21. Intervertebral disk degeneration and repair10.1093/neuros/nyw078 ↗
22. Pathomechanisms of discogenic low back pain in humans and animal models10.1016/j.spinee.2013.07.490 ↗
23. Factors involved in the nutrition of the human lumbar intervertebral disc: cellularity and diffusion of glucose in vitro
24. Structure and biology of the intervertebral disk in health and disease10.1016/j.ocl.2011.07.012 ↗
25. Potential regenerative treatment strategies for intervertebral disc degeneration in dogs10.1186/1746-6148-10-3 ↗
26. Investigation of the laminate structure of lumbar disc anulus fibrosus10.1097/00007632-199005000-00011 ↗
27. Pathomechanism of intervertebral disc degeneration10.1002/jsp2.1076 ↗
28. Current trends in biologics delivery to restore intervertebral disc anabolism10.1016/j.addr.2014.08.008 ↗
29. The role of the vertebral end plate in low back pain10.1055/s-0033-1347298 ↗
30. Factors regulating viable cell density in the intervertebral disc: blood supply in relation to disc height10.1111/joa.12022 ↗
31. Disc morphology in health and disease10.1042/bst0300864 ↗
32. Heritability of low back pain and the role of disc degeneration10.1016/j.pain.2007.01.010 ↗
33. The pathophysiology of disc degeneration: a critical review10.1302/0301-620X.90B10.20910 ↗
34. Effects of tobacco smoking on the degeneration of the intervertebral disc: a finite element study10.1371/journal.pone.0136137 ↗
35. A brief review of the degenerative intervertebral disc disease10.5455/medarh.2019.73.421-424 ↗
36. The cellular pathobiology of the degenerate intervertebral disc and discogenic back pain10.1093/rheumatology/ken396 ↗
37. Degeneration and regeneration of the intervertebral disc: lessons from development10.1242/dmm.006403 ↗
38. Low back pain in relation to lumbar disc degeneration10.1097/00007632-200002150-00016 ↗
39. What is intervertebral disc degeneration, and what causes it?10.1097/01.brs.0000231761.73859.2c ↗
40. The potential role of melatonin in retarding intervertebral disc ageing and degeneration: a systematic review10.1016/j.arr.2021.101394 ↗
41. Disc cell senescence in intervertebral disc degeneration: causes and molecular pathways10.1080/15384101.2016.1152433 ↗
42. Nucleus pulposus notochord cells secrete connective tissue growth factor and up-regulate proteoglycan expression by intervertebral disc chondrocytes10.1002/art.22258 ↗
43. TGF-β1 and GDF5 act synergistically to drive the differentiation of human adipose stromal cells toward nucleus pulposus-like cells10.1002/stem.2249 ↗
44. Non-specific low back pain10.1016/S0140-6736(11)60610-7 ↗
45. An update of current therapeutic approach for Intervertebral Disc Degeneration: a review article
46. Fundamentals of intervertebral disc degeneration10.1016/j.wneu.2021.09.066 ↗
47. Extracellular matrix fragmentation in young, healthy cartilaginous tissues10.22203/eCM.v035a04 ↗
48. Matrix metalloproteinase expression levels suggest distinct enzyme roles during lumbar disc herniation and degeneration10.1007/s00586-009-1031-8 ↗
49. Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration10.1002/art.24291 ↗
50. Inflammatory cytokines in the herniated disc of the lumbar spine10.1097/00007632-199601150-00011 ↗
51. Biologic treatment of mild and moderate intervertebral disc degeneration10.2119/molmed.2014.00145 ↗
52. Advanced glycation end products regulate anabolic and catabolic activities via NLRP3-inflammasome activation in human nucleus pulposus cells10.1111/jcmm.13067 ↗
53. Small molecule natural compound agonist of SIRT3 as a therapeutic target for the treatment of intervertebral disc degeneration10.1038/s12276-018-0173-3 ↗
54. Variation with age in the pattern of type X collagen expression in normal and scoliotic human intervertebral discs10.1007/s002239900524 ↗
55. Mineralization and collagen orientation throughout aging at the vertebral endplate in the human lumbar spine10.1016/j.jsb.2013.08.011 ↗
56. Human cartilaginous endplate degeneration is induced by calcium and the extracellular calcium-sensing receptor in the intervertebral disc10.22203/eCM.v032a09 ↗
57. Intervertebral disc regeneration: do nutrients lead the way?10.1038/nrrheum.2014.91 ↗
58. Small molecule-based treatment approaches for intervertebral disc degeneration: current options and future directions10.7150/thno.48987 ↗
59. Theoretical and uniaxial experimental evaluation of human annulus fibrosus degeneration
60. The relation between intervertebral disc bulging and annular fiber associated strains for simple and complex loading10.1016/j.jbiomech.2007.11.019 ↗
61. Intervertebral disk degeneration and emerging biologic treatments10.5435/00124635-201109000-00005 ↗
62. Why do some intervertebral discs degenerate, when others (in the same spine) do not?10.1002/ca.22404 ↗
63. Tissue engineering strategies for intervertebral disc treatment using functional polymers10.3390/polym11050872 ↗
64. Angiopoietin-like protein 8 expression and association with extracellular matrix metabolism and inflammation during intervertebral disc degeneration10.1111/jcmm.14488 ↗
65. The Nordic back pain subpopulation program--individual patterns of low back pain established by means of text messaging: a longitudinal pilot study10.1186/1746-1340-17-11 ↗
66. Non-specific low back pain10.1016/S0140-6736(16)30970-9 ↗
67. Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging10.1148/radiology.166.1.3336678 ↗
68. Magnetic resonance classification of lumbar intervertebral disc degeneration10.1097/00007632-200109010-00011 ↗
69. Molecular pathogenic factors in symptomatic disc degeneration10.1016/j.spinee.2005.02.010 ↗
70. Prevention and treatment of low back pain: evidence, challenges, and promising directions10.1016/S0140-6736(18)30489-6 ↗
71. Osteoarthritis year in review 2019: epidemiology and therapy10.1016/j.joca.2020.01.002 ↗
72. Stem cells and exosomes: new therapies for intervertebral disc degeneration10.3390/cells10092241 ↗
73. Novel therapeutic strategies for degenerative disc disease: review of cell biology and intervertebral disc cell therapy10.1177/2050312118761674 ↗
74. Operative management of lumbar degenerative disc disease10.4184/asj.2016.10.4.801 ↗
75. 2001 Volvo Award Winner in Clinical Studies: lumbar fusion versus nonsurgical treatment for chronic low back pain: a multicenter randomized controlled trial from the Swedish Lumbar Spine Study Group10.1097/00007632-200112010-00002 ↗
76. Biological approaches to treating intervertebral disk degeneration: devising stem cell therapies10.3727/096368915X688650 ↗
77. Total disc replacement surgery for symptomatic degenerative lumbar disc disease: a systematic review of the literature10.1007/s00586-010-1445-3 ↗
78. Trends and variations in the use of spine surgery10.1097/01.blo.0000198726.62514.75 ↗
79. Challenges and strategies in the repair of ruptured annulus fibrosus10.22203/eCM.v025a01 ↗
80. Innovative strategies for intervertebral disc regenerative medicine: from cell therapies to multiscale delivery systems10.1016/j.biotechadv.2017.11.009 ↗
81. Biological treatment approaches for degenerative disk disease: a literature review of in vivo animal and clinical data10.1055/s-0036-1571955 ↗
82. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy10.1016/j.drudis.2012.05.010 ↗
83. Progress and challenges towards targeted delivery of cancer therapeutics10.1038/s41467-018-03705-y ↗
84. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment10.1016/j.addr.2022.114357 ↗
85. Emerging trends of nanomedicine--an overview10.1111/j.1472-8206.2009.00692.x ↗
86. Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors10.1016/j.biomaterials.2010.03.033 ↗
87. Nano-drug delivery systems in wound treatment and skin regeneration10.1186/s12951-019-0514-y ↗
88. Nanoparticles for tendon healing and regeneration: literature review10.3389/fnagi.2016.00202 ↗
89. Intervertebral disc degeneration: biomaterials and tissue engineering strategies toward precision medicine10.1002/adhm.202102530 ↗
90. Can manganese dioxide microspheres be used as intermediaries to alleviate intervertebral disc degeneration with strengthening drugs?
91. A photopolymerized composite hydrogel and surgical implanting tool for a nucleus pulposus replacement10.1016/j.biomaterials.2016.02.015 ↗
92. Development of dual drug loaded nanosized liposomal formulation by A reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies10.3390/pharmaceutics10030151 ↗
93. Therapeutic nanoplatforms and delivery strategies for neurological disorders10.1186/s40580-018-0168-8 ↗
94. Liposomal drug delivery systems: from concept to clinical applications10.1016/j.addr.2012.09.037 ↗
95. Application of liposome-encapsulated hydroxycamptothecin in the prevention of epidural scar formation in New Zealand white rabbits10.1016/j.spinee.2011.01.028 ↗
96. Advances and challenges of liposome assisted drug delivery10.3389/fphar.2015.00286 ↗
97. Endoscopic transforaminal lumbar interbody fusion without general anesthesia: operative and clinical outcomes in 100 consecutive patients with a minimum 1-year follow-up10.3171/2018.12.FOCUS18701 ↗
98. Intramuscular liposomal bupivacaine decreases length of stay and opioid usage following lumbar spinal fusion10.1097/BSD.0000000000001006 ↗
99. Efficiency of dual siRNA-mediated gene therapy for intervertebral disc degeneration (IVDD)10.1016/j.spinee.2018.10.016 ↗
100. Oxymatrine liposomes for intervertebral disc treatment: formulation, in vitro and vivo assessments10.2147/DDDT.S242493 ↗